Original Literature | Model OverView |
---|---|
Publication
Title
TLR3 in antiviral immunity: key player or bystander?
Affiliation
Viral Immune Evasion Group, Department of Biochemistry, Trinity College Dublin,College Green, Dublin 2, Ireland.
Abstract
Toll-like receptor 3 (TLR3), which recognizes double-stranded (ds)RNA, was thefirst identified antiviral TLR and, because dsRNA is a universal viral molecularpattern, TLR3 has been assumed to have a central role in the host response toviruses. However, this role has recently been questioned by in vivo studies andthe discovery of several other antiviral pattern-recognition receptors. In thisreview, the function of TLR3 in the context of these other receptors, namelyTLR7, 8 and 9 and the newly identified dsRNA-receptor retinoic-acid induciblegene-I (RIG-I) is discussed. Also, recent research concerning the expressionprofile of TLR3, its evasion by viruses and a potential role in crosspriming isaddressed, which reveals a clearer appreciation of the contribution of TLR3 toantiviral immunity.
PMID
16027039
|
Entity
NF-kappaB
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m13
10
infinite
0
TRANSPATH | MO000000058 |
--
IRF-3
--
MO000007694
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m977
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
IFN Type I
--
MO000016658
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m1634
10
infinite
0
TRANSPATH | MO000016658 |
--
RIP3
--
MO000019241
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3825
10
infinite
0
TRANSPATH | MO000019241 |
--
TBK1
--
MO000019331
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3902
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000019331 |
--
cytokines
--
MO000019387
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m3957
10
infinite
0
TRANSPATH | MO000019387 |
--
dsRNA
--
MO000022224
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m119368
10
infinite
0
TRANSPATH | MO000022224 |
--
dsRNA:PKR
--
MO000022225
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m6524
10
infinite
0
TRANSPATH | MO000022225 |
--
eIF-2alpha
--
MO000022570
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m6843
10
infinite
0
InterPro | IPR003029 |
TRANSPATH | MO000022570 |
--
TRIF
--
MO000041125
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m18998
10
infinite
0
TRANSPATH | MO000041125 |
--
dsRNA:TLR3:TRIF
--
MO000041437
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19305
10
infinite
0
TRANSPATH | MO000041437 |
--
dsRNA:TLR3
--
MO000041446
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19314
10
infinite
0
TRANSPATH | MO000041446 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
--
e11
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeLumen
--
--
--
csml-variable:Double
m11
0
infinite
0
--
Lp: TLR2
--
e12
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m12
0
infinite
0
--
LPS: TLR4
--
e13
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m14
0
infinite
0
--
polyI:C
--
e14
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m16
0
infinite
0
--
polyI:C: TLR3
--
e15
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m17
0
infinite
0
--
RIG1
--
e16
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m18
0
infinite
0
--
csml-variable:Double
m19
0
infinite
0
--
dsRNA:TLR3{p}
--
e18
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m20
0
infinite
0
--
csml-variable:Double
m21
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
Lp: TLR2:{p}
--
e20
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m22
0
infinite
0
--
e21
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m23
0
infinite
0
--
LPS: TLR4: TRAM
--
e22
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m24
0
infinite
0
--
LPS: TLR4: TRAM: TRIF
--
e23
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m25
0
infinite
0
--
LPS: TLR4: TRAM: TRIF: TBK1
--
e24
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m26
0
infinite
0
--
IRF-3{activated}
--
e25
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m28
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
IFN Type I
--
e26
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m29
0
infinite
0
--
dsRNA:TLR3:TRIF: TRAF6
--
e27
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m30
0
infinite
0
--
NF-kappaB{activated}
--
e28
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m31
10
infinite
0
TRANSPATH | MO000000058 |
--
dsRNA:TLR3{p}: TRIF: RIP1
--
e29
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m32
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
MAPKs {activated}
--
e30
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m33
10
infinite
0
TRANSPATH | MO000000077 |
--
FADD {activated}
--
e31
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m34
10
infinite
0
InterPro | IPR001875 |
TRANSPATH | MO000016899 |
--
Caspase-8{activated}
--
e32
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m35
10
infinite
0
TRANSPATH | MO000016900 |
--
cytokine
--
e33
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m36
0
infinite
0
--
CCL5
--
e34
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m37
0
infinite
0
--
csml-variable:Double
m38
0
infinite
0
--
csml-variable:Double
m39
0
infinite
0
--
CpG DNA: TLR9
--
e37
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m40
0
infinite
0
--
csml-variable:Double
m41
0
infinite
0
--
ssRNA: TLR7
--
e39
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m42
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
dsRNA: MDA-5
--
e40
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m43
0
infinite
0
--
A46R
--
e41
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m44
0
infinite
0
--
A46R: TRIF
--
e42
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m45
0
infinite
0
--
A52R
--
e43
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m46
0
infinite
0
--
NS3-4a
--
e44
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m47
0
infinite
0
--
csml-variable:Double
m48
0
infinite
0
--
dsRNA:TLR3:TRIF:TBK1:IKK-i
--
e46
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m49
10
infinite
0
TRANSPATH | MO000041441 |
--
IRF-3{activated}
--
e47
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m63
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
IRF-7{activated}
--
e48
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m64
10
infinite
0
TRANSPATH | MO000007702 |
--
eIF-2alpha{p}
--
e49
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m65
0
infinite
0
--
--
e5
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeMembrane
--
--
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
--
e6
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Endosome
--
--
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
dsRNA:TLR3{p}: TRIF: RIP1: FADD
--
e63
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m66
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
p1
p1
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m2549*m3964*0.1
nodelay
--
0
PMID: 16027039, 11607032 The first described ligands for TLRs were of bacterial origin, such as lipopolysaccharide (for TLR4) or peptidoglycan (for TLR2), but since the discovery of double-stranded (ds)RNA as the ligand for TLR3 it has been recognized that TLRs also have a role in the host defense against viruses.
p10
p10
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c26 : 1
stoichiometry:c27 : 1
stoichiometry:c123 : 1
stoichiometry:c28 : 1
m20*m18998*0.1
nodelay
--
0
PMID: 16027039 On dsRNA binding, TLR3 recruits the TIR adaptor molecule TRIF, which induces signaling pathways leading to the activation of IRF3 and NF-kappaB, and the initiation of an apoptotic cascade. PMID: 16027039, 15767257, 15710891 Also, NS3?4a, a protease from HCV, besides targeting some as yet unknown component of the RIG-I pathway, has been described recently to cleave TRIF specifically, thereby abrogating TLR3 signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c29 : 1
stoichiometry:c30 : 1
stoichiometry:c31 : 1
m14*m19005*0.1
nodelay
--
0
PMID: 16027039, 14519765 However, its recruitment to TLR4 is mediated by an additional adaptor molecule, TRIF-related adaptor molecule (TRAM).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c32 : 1
stoichiometry:c34 : 1
stoichiometry:c33 : 1
m24*m18998*0.1
nodelay
--
0
PMID: 16027039 TRIF is not a TLR3-specific adaptor molecule but is also involved in IRF3 activation by TLR4.
p13
p13
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c35 : 1
stoichiometry:c36 : 1
stoichiometry:c37 : 1
stoichiometry:c125 : 1
m3902*m19305*m1599*0.1
nodelay
--
0
PMID: 16027039, 14679297, 12524442 However, TBK1 mediates both TLR4- and TLR3-induced IRF3 activation [30], so the observed differences between TLR3- and TLR4-induced IRF3 activation might be quantitative rather than qualitative. PMID: 16027039, 15210742, 15210743 RIG-I and TLR3 even seem to depend on the same kinases, IKK-i and TBK1, to phosphorylate IRF3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c38 : 1
stoichiometry:c39 : 1
stoichiometry:c40 : 1
m3902*m25*0.1
nodelay
--
0
PMID: 16027039, 14679297, 12524442 However, TBK1 mediates both TLR4- and TLR3-induced IRF3 activation [30], so the observed differences between TLR3- and TLR4-induced IRF3 activation might be quantitative rather than qualitative.
p15
p15
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c41 : 1
stoichiometry:c46 : 1
stoichiometry:c128 : 1
stoichiometry:c42 : 1
m977*m49*0.1
nodelay
--
0
PMID: 16027039 TBK1 recruitment to the amino-terminal region of TRIF mediates IRF3 activation, which is important for the induction of type I interferons. PMID: 16027039, 12566418, 15767367 Whereas A46R, a TIR domain-containing protein, binds to TRIF directly and inhibits poly(I:C)-induced IRF3 activation, A52R potently blocks TLR3 signaling, leading to NF-kappaB activation. PMID: 16027039, 15210742, 15210743 RIG-I and TLR3 even seem to depend on the same kinases, IKK-i and TBK1, to phosphorylate IRF3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c44 : 1
stoichiometry:c45 : 1
m63*0.1
nodelay
--
0
PMID: 16027039 TBK1 recruitment to the amino-terminal region of TRIF mediates IRF3 activation, which is important for the induction of type I interferons. PMID: 16027039, 12646618 In addition, TLR3 engagement leads to a much stronger induction of type I IFNs than does TLR4 signaling
p17
p17
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c43 : 1
stoichiometry:c48 : 1
m183*m19305*0.1
nodelay
--
0
PMID: 16027039, 14530355, 16006187, 11101877 NF-kappaB activation was originally thought to be mediated by TRAF6 11 and 13 but it is now clear that it is at least partially mediated by RIP1, which interacts at the carboxy-terminal of TRIF.
p18
p18
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c49 : 1
stoichiometry:c51 : 1
stoichiometry:c71 : 1
stoichiometry:c116 : 1
stoichiometry:c50 : 1
m13*m30*0.1
nodelay
--
0
PMID: 16027039, 14530355, 16006187, 11101877 NF-kappaB activation was originally thought to be mediated by TRAF6 11 and 13 but it is now clear that it is at least partially mediated by RIP1, which interacts at the carboxy-terminal of TRIF. PMID: 16027039 RIP3 blocks TRIF-induced NF-kappaB activation, and can also by itself induce apoptosis, similarly to RIP1. PMID: 16027039, 12566418, 15767367 Whereas A46R, a TIR domain-containing protein, binds to TRIF directly and inhibits poly(I:C)-induced IRF3 activation, A52R potently blocks TLR3 signaling, leading to NF-kappaB activation.
p19
p19
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c54 : 1
stoichiometry:c52 : 1
stoichiometry:c53 : 1
m15*m19305*0.1
nodelay
--
0
PMID: 16027039, 14530355, 16006187, 11101877 NF-kappaB activation was originally thought to be mediated by TRAF6 11 and 13 but it is now clear that it is at least partially mediated by RIP1, which interacts at the carboxy-terminal of TRIF.
p2
p2
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
m155666*m3961*0.1
nodelay
--
0
PMID: 16027039, 11607032 The first described ligands for TLRs were of bacterial origin, such as lipopolysaccharide (for TLR4) or peptidoglycan (for TLR2), but since the discovery of double-stranded (ds)RNA as the ligand for TLR3 it has been recognized that TLRs also have a role in the host defense against viruses.
p20
p20
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c55 : 1
stoichiometry:c57 : 1
stoichiometry:c72 : 1
stoichiometry:c117 : 1
stoichiometry:c56 : 1
m13*m32*0.1
nodelay
--
0
PMID: 16027039, 14530355, 16006187, 11101877 NF-kappaB activation was originally thought to be mediated by TRAF6 11 and 13 but it is now clear that it is at least partially mediated by RIP1, which interacts at the carboxy-terminal of TRIF. PMID: 16027039 RIP3 blocks TRIF-induced NF-kappaB activation, and can also by itself induce apoptosis, similarly to RIP1. PMID: 16027039, 12566418, 15767367 Whereas A46R, a TIR domain-containing protein, binds to TRIF directly and inhibits poly(I:C)-induced IRF3 activation, A52R potently blocks TLR3 signaling, leading to NF-kappaB activation.
p21
p21
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c58 : 1
stoichiometry:c60 : 1
stoichiometry:c59 : 1
m69*m30*0.1
nodelay
--
0
PMID: 16027039 Ultimately, TLR3 activation leads to the production of proinflammatory cytokines, type I IFNs and the initiation of apoptosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c63 : 1
stoichiometry:c62 : 1
stoichiometry:c61 : 1
m66*0.1
nodelay
--
0
PMID: 16027039, 15814722 RIP1 also links TRIF to the apoptotic cascade [26], which is further mediated by FADD and caspase-8.
p23
p23
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c64 : 1
stoichiometry:c66 : 1
stoichiometry:c65 : 1
m1815*m34*0.1
nodelay
--
0
PMID: 16027039, 15814722 RIP1 also links TRIF to the apoptotic cascade [26], which is further mediated by FADD and caspase-8. PMID: 16027039 RIP3 blocks TRIF-induced NF-kappaB activation, and can also by itself induce apoptosis, similarly to RIP1.
PMID: 16027039, 15814722 RIP1 also links TRIF to the apoptotic cascade [26], which is further mediated by FADD and caspase-8. PMID: 16027039 RIP3 blocks TRIF-induced NF-kappaB activation, and can also by itself induce apoptosis, similarly to RIP1.
p25
p25
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c68 : 1
stoichiometry:c70 : 1
stoichiometry:c69 : 1
m1814*m3825*0.1
nodelay
--
0
PMID: 16027039 RIP3 blocks TRIF-induced NF-kappaB activation, and can also by itself induce apoptosis, similarly to RIP1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c74 : 1
stoichiometry:c73 : 1
m29*0.1
nodelay
--
0
PMID: 16027039 Ultimately, TLR3 activation leads to the production of proinflammatory cytokines, type I IFNs and the initiation of apoptosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c75 : 1
stoichiometry:c76 : 1
m36*0.1
nodelay
--
0
PMID: 16027039 Ultimately, TLR3 activation leads to the production of proinflammatory cytokines, type I IFNs and the initiation of apoptosis.
p28
p28
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c78 : 1
stoichiometry:c80 : 1
stoichiometry:c79 : 1
m13*m25*0.1
nodelay
--
0
PMID: 16027039, 14557267 Consistent with this, IFN-stimulated response element induction by TLR4, but not by TLR3, requires the NF-kappaB subunit p65.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c81 : 1
stoichiometry:c77 : 1
m33*0.1
nodelay
--
0
PMID: 16027039, 15731229, 15579900 Apart from this somewhat specific case, it was demonstrated that cytokines are induced in a TLR3-dependent manner in bronchial epithelial cell lines, on infection with the ssRNA viruses respiratory syncytial virus or influenza, although no animal models were used to verify a role for TLR3 in vivo.
p3
p3
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m3965*m119368*0.1
nodelay
--
0
PMID: 16027039, 11607032 The first described ligands for TLRs were of bacterial origin, such as lipopolysaccharide (for TLR4) or peptidoglycan (for TLR2), but since the discovery of double-stranded (ds)RNA as the ligand for TLR3 it has been recognized that TLRs also have a role in the host defense against viruses.
p30
p30
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c85 : 1
stoichiometry:c124 : 1
stoichiometry:c84 : 1
m977*m26*0.1
nodelay
--
0
PMID: 16027039 TRIF is not a TLR3-specific adaptor molecule but is also involved in IRF3 activation by TLR4. PMID: 16027039, 12566418, 15767367 Whereas A46R, a TIR domain-containing protein, binds to TRIF directly and inhibits poly(I:C)-induced IRF3 activation, A52R potently blocks TLR3 signaling, leading to NF-kappaB activation.
p31
p31
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c82 : 1
stoichiometry:c89 : 1
stoichiometry:c86 : 1
m95041*m19314*0.1
nodelay
--
0
PMID: 16027039, 15731229 Interestingly, however, Rudd et al. found that respiratory syncytial virus-induced CXCL10 and CCL5 production, but not CXCL8 production or viral replication, were impaired in the absence of TLR3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c90 : 1
stoichiometry:c88 : 1
m38*m19314*0.1
nodelay
--
0
PMID: 16027039, 15731229 Interestingly, however, Rudd et al. found that respiratory syncytial virus-induced CXCL10 and CCL5 production, but not CXCL8 production or viral replication, were impaired in the absence of TLR3.
p33
p33
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c91 : 1
stoichiometry:c92 : 1
stoichiometry:c93 : 1
m19828*m39*0.1
nodelay
--
0
PMID: 16027039, 12900525, 14976261, 14976262 With the discovery that unmethylated viral CpG-DNA (from herpes simplex virus-2) can stimulate TLR9 [4] and the identification of ssRNA (from influenza virus and HIV-1) as the ligand for TLR7. PMID: 16027039, 15034168, 14993594, 12900525 TLR7 is involved in the response to the ssRNA viruses VSV and influenza [5], whereas TLR9 has a role in responding to the dsDNA viruses MCMV [6], herpes simplex virus-1 (HSV-1) and HSV-2.
p34
p34
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c95 : 1
stoichiometry:c96 : 1
m19940*m41*0.1
nodelay
--
0
PMID: 16027039, 12900525, 14976261, 14976262 With the discovery that unmethylated viral CpG-DNA (from herpes simplex virus-2) can stimulate TLR9 [4] and the identification of ssRNA (from influenza virus and HIV-1) as the ligand for TLR7. PMID: 16027039, 15034168, 14993594, 12900525 TLR7 is involved in the response to the ssRNA viruses VSV and influenza [5], whereas TLR9 has a role in responding to the dsDNA viruses MCMV [6], herpes simplex virus-1 (HSV-1) and HSV-2.
p35
p35
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c97 : 1
stoichiometry:c98 : 1
stoichiometry:c99 : 1
m119368*m1055*0.1
nodelay
--
0
PMID: 16027039, 12773480 Before the discovery of TLR3, it was well known that cells detected viral dsRNA through dsRNA-dependent protein kinase (PKR), which, in response, inhibits host translation by phosphorylating the initiation factor, the alpha subunit of eukaryotic protein synthesis initiation factor 2, and, similar to TLR3, activates NF-kappaB.
p36
p36
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c100 : 1
stoichiometry:c102 : 1
stoichiometry:c101 : 1
m977*m19*0.1
nodelay
--
0
PMID: 16027039, 15208624 Apart from its helicase domain, RIG-I also contains a tandem caspase recruitment domain (CARD), which transmits signals leading to NF-kappaB and IRF3 activation.
p37
p37
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c105 : 1
stoichiometry:c104 : 1
m13*m19*0.1
nodelay
--
0
PMID: 16027039, 15208624 Apart from its helicase domain, RIG-I also contains a tandem caspase recruitment domain (CARD), which transmits signals leading to NF-kappaB and IRF3 activation.
p38
p38
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c106 : 1
stoichiometry:c107 : 1
stoichiometry:c108 : 1
m76904*m119368*0.1
nodelay
--
0
PMID: 16027039, 15208624 Along with RIG-I, a homologous CARD domain-containing helicase, melanoma differentiation-associated gene-5 (mda-5), was identified and shown to have similar effects in dsRNA signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c109 : 1
stoichiometry:c110 : 1
stoichiometry:c111 : 1
m44*m18998*0.1
nodelay
--
0
PMID: 16027039, 12566418, 15767367 Whereas A46R, a TIR domain-containing protein, binds to TRIF directly and inhibits poly(I:C)-induced IRF3 activation, A52R potently blocks TLR3 signaling, leading to NF-kappaB activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c12 : 1
m16*m3965*0.1
nodelay
--
0
PMID: 16027039 It is now clear that TLR3 can mediate responses to the synthetic analog of viral dsRNA, polyriboinosinic:polyribocytidylic acid [poly(I:C)], which has been used extensively in experimental studies to mimic viral infection.
p40
p40
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c112 : 1
stoichiometry:c114 : 1
stoichiometry:c115 : 1
stoichiometry:c126 : 1
stoichiometry:c127 : 1
stoichiometry:c113 : 1
m977*m17*m3902*m1599*0.1
nodelay
--
0
PMID: 16027039, 12566418, 15767367 Whereas A46R, a TIR domain-containing protein, binds to TRIF directly and inhibits poly(I:C)-induced IRF3 activation, A52R potently blocks TLR3 signaling, leading to NF-kappaB activation. PMID: 16027039, 15210742, 15210743 RIG-I and TLR3 even seem to depend on the same kinases, IKK-i and TBK1, to phosphorylate IRF3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c122 : 1
stoichiometry:c121 : 1
m47*0.1
nodelay
--
0
PMID: 16027039, 15767257, 15710891 Also, NS3?4a, a protease from HCV, besides targeting some as yet unknown component of the RIG-I pathway, has been described recently to cleave TRIF specifically, thereby abrogating TLR3 signaling.
p42
p42
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c129 : 1
stoichiometry:c131 : 1
stoichiometry:c130 : 1
m13*m6524*0.1
nodelay
--
0
PMID: 16027039, 15208624, 14982987, 12773480 This is particularly perplexing because the signaling pathways elicited by TLR3, PKR and RIG-I overlap significantly, in that all three activate NF-kappaB, whereas RIG-I and TLR3 (and possibly also PKR) activate IRF3 and IRF7.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c118 : 1
stoichiometry:c132 : 1
stoichiometry:c119 : 1
m28*m21*0.1
nodelay
--
0
PMID: 16027039,12509442, 15733829, 15502848 Recently, it has been demonstrated that TLR3 is phosphorylated at two tyrosine residues on activation, and that phosphatidylinositol 3-kinase (PI3K; PtdIns 3-kinase) is recruited subsequently to these residues [18], a process that seems to be required for full activation of IRF3.
p44
p44
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c120 : 1
stoichiometry:c136 : 1
stoichiometry:c133 : 1
m980*m49*0.1
nodelay
--
0
PMID: 16027039, 15208624, 14982987, 12773480 This is particularly perplexing because the signaling pathways elicited by TLR3, PKR and RIG-I overlap significantly, in that all three activate NF-kappaB, whereas RIG-I and TLR3 (and possibly also PKR) activate IRF3 and IRF7.
p45
p45
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c134 : 1
stoichiometry:c137 : 1
stoichiometry:c135 : 1
m980*m19*0.1
nodelay
--
0
PMID: 16027039, 15208624, 14982987, 12773480 This is particularly perplexing because the signaling pathways elicited by TLR3, PKR and RIG-I overlap significantly, in that all three activate NF-kappaB, whereas RIG-I and TLR3 (and possibly also PKR) activate IRF3 and IRF7.
PMID: 16027039, 11232238, 15029200, 15711932 Furthermore, apoptosis, is induced not only by TLR3 but also by PKR and probably by RIG-I.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c139 : 1
m42*0.1
nodelay
--
0
PMID: 16027039, 15688039, 14751761, 12480255 Importantly, this differential expression profile is reflected in distinct gene induction patterns: pDCs produce high amounts of type I IFNs (predominantly IFN-¦Á) in response to TLR7 or TLR9 engagement, whereas myeloid DCs mainly produce IL-12 and IFN-beta on TLR3 stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c141 : 1
stoichiometry:c140 : 1
m40*0.1
nodelay
--
0
PMID: 16027039, 15688039, 14751761, 12480255 Importantly, this differential expression profile is reflected in distinct gene induction patterns: pDCs produce high amounts of type I IFNs (predominantly IFN-¦Á) in response to TLR7 or TLR9 engagement, whereas myeloid DCs mainly produce IL-12 and IFN-beta on TLR3 stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c145 : 1
stoichiometry:c143 : 1
m42*0.1
nodelay
--
0
PMID: 16027039, 15688039, 14751761, 12480255 Importantly, this differential expression profile is reflected in distinct gene induction patterns: pDCs produce high amounts of type I IFNs (predominantly IFN-¦Á) in response to TLR7 or TLR9 engagement, whereas myeloid DCs mainly produce IL-12 and IFN-beta on TLR3 stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c14 : 1
stoichiometry:c15 : 1
m18*m119368*0.1
nodelay
--
0
PMID: 16027039, 15208624 Furthermore, an additional pattern-recognition receptor (PRR) for dsRNA, retinoic-acid inducible gene-I (RIG-I), has recently been identified [9] and seems to be emerging as a key player in the induction of an interferon response by viruses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c146 : 1
stoichiometry:c144 : 1
m40*0.1
nodelay
--
0
PMID: 16027039, 15688039, 14751761, 12480255 Importantly, this differential expression profile is reflected in distinct gene induction patterns: pDCs produce high amounts of type I IFNs (predominantly IFN-¦Á) in response to TLR7 or TLR9 engagement, whereas myeloid DCs mainly produce IL-12 and IFN-beta on TLR3 stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c148 : 1
stoichiometry:c150 : 1
m63*0.1
nodelay
--
0
PMID: 16027039, 15688039, 14751761, 12480255 Importantly, this differential expression profile is reflected in distinct gene induction patterns: pDCs produce high amounts of type I IFNs (predominantly IFN-¦Á) in response to TLR7 or TLR9 engagement, whereas myeloid DCs mainly produce IL-12 and IFN-beta on TLR3 stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c149 : 1
stoichiometry:c147 : 1
m63*0.1
nodelay
--
0
PMID: 16027039, 15688039, 14751761, 12480255 Importantly, this differential expression profile is reflected in distinct gene induction patterns: pDCs produce high amounts of type I IFNs (predominantly IFN-¦Á) in response to TLR7 or TLR9 engagement, whereas myeloid DCs mainly produce IL-12 and IFN-beta on TLR3 stimulation.
p53
p53
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c151 : 1
stoichiometry:c153 : 1
stoichiometry:c152 : 1
m6843*m6524*0.1
nodelay
--
0
PMID: 16027039, 12773480 Before the discovery of TLR3, it was well known that cells detected viral dsRNA through dsRNA-dependent protein kinase (PKR), which, in response, inhibits host translation by phosphorylating the initiation factor, the alpha subunit of eukaryotic protein synthesis initiation factor 2, and, similar to TLR3, activates NF-kappaB.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c154 : 1
stoichiometry:c156 : 1
stoichiometry:c155 : 1
m32*m1814*0.1
nodelay
--
0
PMID: 16027039, 14739303, 15814722 The pro-apoptotic effect is further mediated by Fas-associated death domain (FADD) and caspase-8 and it is conceivable that RIP1 engages FADD through its death domain.
p6
p6
cso30:i:ME_Phosphorylation
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
m19314*0.1
nodelay
--
0
PMID: 16027039,12509442, 15733829, 15502848 Recently, it has been demonstrated that TLR3 is phosphorylated at two tyrosine residues on activation, and that phosphatidylinositol 3-kinase (PI3K; PtdIns 3-kinase) is recruited subsequently to these residues [18], a process that seems to be required for full activation of IRF3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c18 : 1
stoichiometry:c19 : 1
stoichiometry:c20 : 1
m20*m27*0.1
nodelay
--
0
PMID: 16027039,12509442, 15733829, 15502848 Recently, it has been demonstrated that TLR3 is phosphorylated at two tyrosine residues on activation, and that phosphatidylinositol 3-kinase (PI3K; PtdIns 3-kinase) is recruited subsequently to these residues [18], a process that seems to be required for full activation of IRF3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c21 : 1
stoichiometry:c22 : 1
m12*0.1
nodelay
--
0
PMID: 16027039, 11101877 The only other TLR that has been shown to be phosphorylated and to recruit PI3K is TLR2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c23 : 1
stoichiometry:c25 : 1
stoichiometry:c24 : 1
m22*m27*0.1
nodelay
--
0
PMID: 16027039, 11101877 The only other TLR that has been shown to be phosphorylated and to recruit PI3K is TLR2.
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--